Download Supplementary Figure S4

NCI-H508-HER2
A
TRAS (μg/ml)
_
LAP (μM)
_
_
_
_
_
_
_
_
NCI-N87
_
_
_
_
_
_
_
_
_
_
_
pERK 1/2
T202/Y204
ERK 1/2
pAKT
S473
AKT
B
NCI-H508-HER2
TRAS (10 μg/ml)
_
LAP (0.2 μM)
_
_
_
_
_
_
_
_
_
NCI-N87
_
_
_
_
_
_
_
_
_
_
hr
hr
pERK 1/2
T202/Y204
ERK 1/2
pAKT
S473
AKT
Supplementary Figure S4. Signaling consequences of treatment with trastuzumab, lapatinib and
their combination in HER2-positive colorectal and gastric cancer cells: Effects on downstream
transducers
A, Activation status/phosphorylation of HER downstream transducers (ERK and AKT) in NCI-H508HER2 and NCI-N87 cells in dose-response experiments. Cells were treated with the indicated
concentrations of trastuzumab, lapatinib or the combination of both for 2 hours. Cell extracts were
immunoblotted with the indicated antibodies. B, Activation status/phosphorylation of ERK and AKT in
NCI-H508-HER2 and NCI-N87 cells in time-course experiments. Trastuzumab, lapatinib or the
combination of both were added to cells at the beginning of the experiment at the indicated
concentrations. Cells were incubated in the presence of the inhibitor(s) for the indicated times and
lysates subjected to Western blot analysis. TRAS, trastuzumab; LAP, lapatinib. See Figure 3A and 3B
for a comparison of MSD data.
Leto et al., Supplementary Figure S4